Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) 3-Year EBITDA Growth Rate : -5.20% (As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co 3-Year EBITDA Growth Rate?

Shenzhen Neptunus Interlong Bio-Technique Co's EBITDA per Share for the three months ended in Jun. 2024 was HK$0.00.

During the past 12 months, Shenzhen Neptunus Interlong Bio-Technique Co's average EBITDA Per Share Growth Rate was -87.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -5.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -2.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shenzhen Neptunus Interlong Bio-Technique Co was 13.90% per year. The lowest was -6.00% per year. And the median was 1.70% per year.

Competitive Comparison of Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate falls into.

Shenzhen Neptunus Interlong Bio-Technique Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shenzhen Neptunus Interlong Bio-Technique Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

95 Queensway, 18th Floor, United Centre, Admiralty, Hong Kong, HKG

Website

https://www.interlong.com

Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sales of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines; and the Sales and distribution of medicines and healthcare products. The majority of revenue is generated from the Manufacturing and selling of medicines.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines